Axsome Therapeutics (AXSM) Total Debt (2016 - 2026)

Axsome Therapeutics has disclosed Total Debt across 11 years of filings, most recently posting $129.0 million for Q1 2026.

• Total Debt for Q1 2026 came in at $129.0 million, down 32.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $129.0 million (down 32.1% YoY), and the FY2025 annual result was $127.8 million, down 29.3% from the prior year.
• Total Debt came in at $129.0 million for Q1 2026 at Axsome Therapeutics, up from $127.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $190.0 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• The 5-year median for Total Debt is $180.7 million (2024), against an average of $150.4 million.
• Across the five-year window, Total Debt jumped 211.51% in 2023 and sank 32.32% in 2025, its largest moves.
• Axsome Therapeutics' Total Debt stood at $100.2 million in 2022, then surged by 84.18% to $184.5 million in 2023, then slipped by 2.04% to $180.7 million in 2024, then dropped by 29.3% to $127.8 million in 2025, then increased by 0.97% to $129.0 million in 2026.
• The last three Total Debt figures came in at $129.0 million (Q1 2026), $127.8 million (Q4 2025), and $127.3 million (Q3 2025), per Business Quant data.